

Matthew S Miller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8821194/publications.pdf>

Version: 2024-02-01

62
papers

3,929
citations

201385

27
h-index

138251

58
g-index

74
all docs

74
docs citations

74
times ranked

6756
citing authors

#	ARTICLE	IF	CITATIONS
1	Gut microbiota-based vaccination engages innate immunity to improve blood glucose control in obese mice. <i>Molecular Metabolism</i> , 2022, 55, 101404.	3.0	4
2	A Universal DNA Aptamer that Recognizes Spike Proteins of Diverse SARS-CoV-2 Variants of Concern. <i>Chemistry - A European Journal</i> , 2022, 28, .	1.7	30
3	Antibody Responses to Third-Dose mRNA Vaccines in Nursing Home and Assisted Living Residents. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 444-446.	1.2	8
4	Cigarette smoke augments CSF3 expression in neutrophils to compromise alveolar capillary barrier function during influenza infection. <i>European Respiratory Journal</i> , 2022, 60, 2102049.	3.1	5
5	Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2. <i>Cell</i> , 2022, 185, 896-915.e19.	13.5	189
6	Inactivated and live-attenuated seasonal influenza vaccines boost broadly neutralizing antibodies in children. <i>Cell Reports Medicine</i> , 2022, 3, 100509.	3.3	1
7	A Universal DNA Aptamer that Recognizes Spike Proteins of Diverse SARS-CoV-2 Variants of Concern. <i>Chemistry - A European Journal</i> , 2022, 28, e202200524.	1.7	9
8	Engineered Nanoparticle Applications for Recombinant Influenza Vaccines. <i>Molecular Pharmaceutics</i> , 2021, 18, 576-592.	2.3	14
9	Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects. <i>Viruses</i> , 2021, 13, 697.	1.5	36
10	Experimental and natural evidence of SARS-CoV-2-infection-induced activation of type I interferon responses. <i>IScience</i> , 2021, 24, 102477.	1.9	49
11	A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	15
12	Cigarette smoke exposure attenuates the induction of antigen-specific IgA in the murine upper respiratory tract. <i>Mucosal Immunology</i> , 2021, 14, 1067-1076.	2.7	8
13	Neutrophils and Influenza: A Thin Line between Helpful and Harmful. <i>Vaccines</i> , 2021, 9, 597.	2.1	20
14	IgA potentiates NETosis in response to viral infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	35
15	Diverse high-affinity DNA aptamers for wild-type and B.1.1.7 SARS-CoV-2 spike proteins from a pre-structured DNA library. <i>Nucleic Acids Research</i> , 2021, 49, 7267-7279.	6.5	77
16	High-Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wild-Type and B.1.1.7 SARS-CoV-2 in Unprocessed Saliva. <i>Angewandte Chemie</i> , 2021, 133, 24468-24476.	1.6	21
17	High-Affinity Dimeric Aptamers Enable the Rapid Electrochemical Detection of Wild-Type and B.1.1.7 SARS-CoV-2 in Unprocessed Saliva. <i>Angewandte Chemie - International Edition</i> , 2021, 60, 24266-24274.	7.2	101
18	Probe design for simultaneous, targeted capture of diverse metagenomic targets. <i>Cell Reports Methods</i> , 2021, 1, 100069.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Potential of long-acting β_2 -agonist and glucocorticoid responses in human airway epithelial cells by modulation of intracellular cAMP. <i>Respiratory Research</i> , 2021, 22, 266.	1.4	2
20	Effect of inactivated influenza vaccination on human coronavirus infection: Secondary analysis of a randomized trial in Hutterite colonies. <i>Vaccine</i> , 2021, 39, 7058-7065.	1.7	3
21	Lasting Changes to Circulating Leukocytes in People with Mild SARS-CoV-2 Infections. <i>Viruses</i> , 2021, 13, 2239.	1.5	10
22	Antibody Responses 3-5 Months Post-Vaccination with mRNA-1273 or BNT163b2 in Nursing Home Residents. <i>Journal of the American Medical Directors Association</i> , 2021, 22, 2512-2514.	1.2	13
23	Repeated Seasonal Influenza Vaccination: How Much Is Too Much of a Good Thing?. <i>Journal of Infectious Diseases</i> , 2020, 222, 173-175.	1.9	4
24	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. <i>Cell Reports Medicine</i> , 2020, 1, 100126.	3.3	200
25	Bat Influenza Viruses: Making a Double Agent of MHC Class II. <i>Trends in Microbiology</i> , 2020, 28, 703-706.	3.5	5
26	Gene expression and <i>in situ</i> protein profiling of candidate SARS-CoV-2 receptors in human airway epithelial cells and lung tissue. <i>European Respiratory Journal</i> , 2020, 56, 2001123.	3.1	138
27	Immunological considerations for COVID-19 vaccine strategies. <i>Nature Reviews Immunology</i> , 2020, 20, 615-632.	10.6	806
28	Isolation, Sequence, Infectivity, and Replication Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2. <i>Emerging Infectious Diseases</i> , 2020, 26, 2054-2063.	2.0	118
29	Age-Specific Incidence of Influenza A Responds to Change in Virus Subtype Dominance. <i>Clinical Infectious Diseases</i> , 2020, 71, e195-e198.	2.9	8
30	Predicting the recombination potential of severe acute respiratory syndrome coronavirus 2 and Middle East respiratory syndrome coronavirus. <i>Journal of General Virology</i> , 2020, 101, 1251-1260.	1.3	12
31	Comparative Immunogenicity of the 2014-2015 Northern Hemisphere Trivalent IIV and LAIV against Influenza A Viruses in Children. <i>Vaccines</i> , 2019, 7, 87.	2.1	7
32	Determinants of Influenza Mortality Trends: Age-Period-Cohort Analysis of Influenza Mortality in the United States, 1959-2016. <i>Demography</i> , 2019, 56, 1723-1746.	1.2	15
33	Thermal Stabilization of Viral Vaccines in Low-Cost Sugar Films. <i>Scientific Reports</i> , 2019, 9, 7631.	1.6	23
34	Excipient selection for thermally stable enveloped and non-enveloped viral vaccine platforms in dry powders. <i>International Journal of Pharmaceutics</i> , 2019, 561, 66-73.	2.6	22
35	Original Antigenic Sin: How First Exposure Shapes Lifelong Anti-Influenza Virus Immune Responses. <i>Journal of Immunology</i> , 2019, 202, 335-340.	0.4	141
36	Reviewing the evidence for viruses as environmental risk factors for ALS: A new perspective. <i>Cytokine</i> , 2018, 108, 173-178.	1.4	22

#	ARTICLE	IF	CITATIONS
37	Pandemic Paradox: Early Life H2N2 Pandemic Influenza Infection Enhanced Susceptibility to Death during the 2009 H1N1 Pandemic. <i>MBio</i> , 2018, 9, .	1.8	35
38	Reporting and evaluating influenza virus surveillance data: An argument for incidence by single year of age. <i>Vaccine</i> , 2018, 36, 6249-6252.	1.7	6
39	“Gnoti Seauton” Leveraging the Host Response to Improve Influenza Virus Vaccine Efficacy. <i>Vaccines</i> , 2018, 6, 23.	2.1	9
40	Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice. <i>Nature Communications</i> , 2017, 8, 846.	5.8	134
41	Regulation of kynurenine biosynthesis during influenza virus infection. <i>FEBS Journal</i> , 2017, 284, 222-236.	2.2	56
42	Autoimmune VariantPTPN22C1858T Is Associated With Impaired Responses to Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2016, 214, 248-257.	1.9	13
43	CARMA3 Is a Host Factor Regulating the Balance of Inflammatory and Antiviral Responses against Viral Infection. <i>Cell Reports</i> , 2016, 14, 2389-2401.	2.9	23
44	Abnormal regulation of the antiviral response in neurological/neurodegenerative diseases. <i>Cytokine</i> , 2016, 88, 251-258.	1.4	7
45	Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11931-11936.	3.3	153
46	Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Induce Potent Phagocytosis of Immune Complexes by Neutrophils in an Fc-Dependent Manner. <i>MBio</i> , 2016, 7, .	1.8	100
47	Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E5944-E5951.	3.3	108
48	Hemagglutinin Stalk Immunity Reduces Influenza Virus Replication and Transmission in Ferrets. <i>Journal of Virology</i> , 2016, 90, 3268-3273.	1.5	69
49	Broadly Neutralizing Anti-Influenza Virus Antibodies: Enhancement of Neutralizing Potency in Polyclonal Mixtures and IgA Backbones. <i>Journal of Virology</i> , 2015, 89, 3610-3618.	1.5	80
50	Is Antigenic Sin Always “Original”? Re-examining the Evidence Regarding Circulation of a Human H1 Influenza Virus Immediately Prior to the 1918 Spanish Flu. <i>PLoS Pathogens</i> , 2015, 11, e1004615.	2.1	36
51	Measuring the neutralization potency of influenza A virus hemagglutinin stalk/stem-binding antibodies in polyclonal preparations by microneutralization assay. <i>Methods</i> , 2015, 90, 95-100.	1.9	34
52	Senataxin suppresses the antiviral transcriptional response and controls viral biogenesis. <i>Nature Immunology</i> , 2015, 16, 485-494.	7.0	50
53	Peering into the Crystal Ball: Influenza Pandemics and Vaccine Efficacy. <i>Cell</i> , 2014, 157, 294-299.	13.5	26
54	Assessment of Influenza Virus Hemagglutinin Stalk-Based Immunity in Ferrets. <i>Journal of Virology</i> , 2014, 88, 3432-3442.	1.5	128

#	ARTICLE	IF	CITATIONS
55	Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13133-13138.	3.3	197
56	Neutralizing Antibodies Against Previously Encountered Influenza Virus Strains Increase over Time: A Longitudinal Analysis. Science Translational Medicine, 2013, 5, 198ra107.	5.8	157
57	1976 and 2009 H1N1 Influenza Virus Vaccines Boost Anti-Hemagglutinin Stalk Antibodies in Humans. Journal of Infectious Diseases, 2013, 207, 98-105.	1.9	77
58	Age-Specific Mortality During the 1918 Influenza Pandemic: Unravelling the Mystery of High Young Adult Mortality. PLoS ONE, 2013, 8, e69586.	1.1	122
59	Adenovirus E1A Directly Targets the E2F/DP-1 Complex. Journal of Virology, 2011, 85, 8841-8851.	1.5	40
60	Onset of Human Cytomegalovirus Replication in Fibroblasts Requires the Presence of an Intact Vimentin Cytoskeleton. Journal of Virology, 2009, 83, 7015-7028.	1.5	52
61	Recombination Potential of SARS-CoV-2 and MERS-CoV. SSRN Electronic Journal, 0, , .	0.4	0
62	Differential Biodistribution of Adenoviral-Vectored Vaccine Following Intranasal and Endotracheal Deliveries Leads to Different Immune Outcomes. Frontiers in Immunology, 0, 13, .	2.2	14